Editas Medicine, Inc. EDIT
Set alert
As of Nov 3, 2:39 PM ET
- YTD
- +25.85%
- 1 year
- -15.69%
- Open
- 2.61
- Prev close
- 2.57
- Mkt cap
- 395.47M
- Vol
- 1.05M
- Avg vol
- 2.69M
- EPS
- -0.68
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.57
- High
- 2.71
- Forward P/E
- -0.53
- Beta
- 2.01
- Short ratio
- 6.70
- Inst. own
- 70.94%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.60
- 200-d avg
- 4.55
- 1y target
- 3.67
5m chart
Built from the cached five-day intraday bars.
Signals (73)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Nov 3, 2:30 PM | 9 minutes ago |
| MACD: Sell Signal | Nov 3, 1:35 PM | 1 hour ago |
| MACD: Buy Signal | Nov 3, 1:30 PM | 1 hour ago |
| MACD: Sell Signal | Nov 3, 1:25 PM | 1 hour ago |
| MACD: Buy Signal | Nov 3, 1:00 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 11:40 AM | 2 hours ago |
| SMA: Bullish | Nov 3, 11:05 AM | 3 hours ago |
| SMA: Bullish | Nov 3, 11:05 AM | 3 hours ago |
| SMA: Bearish | Nov 3, 10:45 AM | 3 hours ago |
| MACD: Sell Signal | Nov 3, 10:30 AM | 4 hours ago |
| SMA: Bearish | Nov 3, 10:05 AM | 4 hours ago |
| RSI: Overbought | Nov 3, 9:55 AM | 4 hours ago |
| SMA: Bullish | Nov 3, 9:30 AM | 5 hours ago |
| RSI: Overbought | Nov 3, 9:30 AM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 2:55 PM | 23 hours ago |
| RSI: Oversold | Nov 2, 2:30 PM | 1 day ago |
| RSI: Oversold | Nov 2, 1:50 PM | 1 day ago |
| RSI: Oversold | Nov 2, 1:40 PM | 1 day ago |
| MACD: Sell Signal | Nov 2, 1:30 PM | 1 day ago |
| MACD: Buy Signal | Nov 2, 12:55 PM | 1 day ago |
Newest 20 of 73.
Discussion (212)
Sign in to join the discussion
ZirK EDIT 1 year ago #1Bagholder for very long time
Xsman EDIT 2 years ago #28.31 first target
$EDIT ⏰?
Jitin Goyal EDIT 3 years ago #5Rumours circulating that Editas has received an offer to be acquired at a valuation of $1.5 bn
Jitin Goyal EDIT 3 years ago #6This stock will be trading at $17-20 in a couple of weeks.
Jitin Goyal EDIT 3 years ago #7Massively undervalued stock. Average analyst price target is $16, highest is $30. Crazy that it’s trading at such low levels right now.
Jitin Goyal EDIT 3 years ago #8Stifel analyst Dae Gon Ha upgraded Editas Medicine (NASDAQ: EDIT) from Hold to Buy with a price target of $17.00 (from $9.00).
The analyst comments "We are upgrading EDIT shares to Buy and increasing TP to $17 (vs. $9 previously). We think EDIT-301's (sickle cell disease [SCD]) progress has received minimal credit from investors. But with YE23 goal to dose n=20, in addition to important regulatory insights expected from exa-cel (CRSP, covered by Stifel colleague Ben Burnett), we think EDIT-301 deserves a fresh look. Within, we discuss the disconnect between EDIT and CRSP valuations - at comparable time points in development, EDIT-301's clinical profile thus far (vs. exa-cel), our optimism - both clinically and regulatory - in EDIT-301's strategy (i.e., HBG1/2 promoter region), market receptivity - and TAM - for follow-on gene editing like EDIT-301, and potential upside from the IP dispute.
Jitin Goyal EDIT 3 years ago #9
Petroni Petroni EDIT 3 years ago #10$EDIT suck my dick Cathy Wood ?
Bitch, dumb as a bag of rocks ?